RHHBY Earnings — Roche Holding AG
OTC · Healthcare · Drug Manufacturers - General
Updated
When is RHHBY's next earnings date?
Roche Holding AG (RHHBY) has not announced its next earnings date yet. Its most recent earnings report was on Thursday, July 21, 2022.
How did RHHBY do in its last earnings report?
In its most recent report on Jul 21, 2022, Roche Holding AG posted EPS of $1.52 versus the $1.41 estimate, a beat. Revenue was $33.31B against a $32.97B estimate.
How much does RHHBY stock move after earnings?
RHHBY beat EPS estimates in 3 of its last 6 reported quarters.
About Roche Holding AG
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
🤖 AI Earnings Analysis
RHHBY’s sefaxersen Phase III data showed significantly reduced proteinuria in IgAN, strengthening its pipeline; its 20.33% profit margin provides a strong earnings base.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2022-07-21 | 1.41 | 1.52 | — | $33.31B | ✅ Beat | — | — | — | |
| 2022-02-03 | 1.32 | 1.26 | — | $35.34B | ❌ Miss | — | — | — | |
| 2021-07-22 | 1.38 | 1.44 | — | $33.44B | ✅ Beat | — | — | — | |
| 2021-02-01 | 1.24 | 1.21 | — | $32.15B | ❌ Miss | — | — | — | |
| 2020-07-23 | 1.41 | 1.41 | — | $31.63B | ➖ Inline | — | — | — | |
| 2020-01-30 | 1.16 | 1.17 | — | $32.22B | ✅ Beat | — | — | — |
Showing last 6 quarters.